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Calcitonin Response to Naturally Occurring Ionized
Hypercalcemia in Cats with Chronic Kidney Disease
D.H.N. Van den Broek , R.F. Geddes, T.L. Williams, Y.-M. Chang , J. Elliott, and R.E. Jepson
Background: Hypercalcemia is commonly associated with chronic kidney disease (CKD) in cats.
Objectives: To explore the calcitonin response to naturally occurring ionized hypercalcemia in cats with azotemic CKD, and to assess the
relationship of plasma calcitonin with ionized calcium, alkaline phosphatase (ALP), and urinary calcium excretion.
Animals: Thirty-three client-owned cats with azotemic CKD and ionized hypercalcemia from first opinion practice.
Methods: Cohort study. Calcitonin was measured with an immunoradiometric assay in heparinized plasma. Simple correlations were
assessed with Kendall’s rank correlation, and the within-subject correlations of calcitonin with ionized calcium and other
clinicopathological variables were calculated with a bivariate linear mixed effects model.
Results: Calcitonin concentrations above the lower limit of detection (>1.2 pg/mL; range, 1.7–87.2 pg/mL) were observed in 11 of 33
hypercalcemic cats (responders). Blood ionized calcium concentration did not differ significantly between responders (median, 1.59
[1.46, 1.66] mmol/L) and nonresponders (median, 1.48 [1.43, 1.65] mmol/L; P5 0.22). No evidence was found for calcitonin and
ionized calcium to correlate between cats (sb5 0.14; P5 0.31; n5 33), but significant positive correlation was evident within
individual responders over time (within-subject correlation coefficient [rwithin], 0.83; 95% confidence interval [CI], 0.63–0.92).
Calcitonin correlated negatively over time with plasma ALP (rwithin,20.55; 95% CI,20.79 to20.16).
Conclusions and Clinical Importance: Calcitonin does not appear to have an important role in calcium metabolism in cats with CKD.
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C hronic kidney disease (CKD) is the 7th most frequentlyencountered disorder in cats in general practice in Eng-
land,1 with a disease prevalence of 30–80% in cats over 10
years old,2,3 and is commonly associated with hypercalce-
mia.4–6 The kidneys play an important role in calcium regu-
lation,7,8 but the etiology of hypercalcemia in cats with
CKD is not completely understood.9 Derangements in hor-
mones involved in calcium homeostasis, such as secondary
renal hyperparathyroidism, are common and occur early in
cats as part of CKD-mineral and bone disorder.10–12
Although it is traditionally stated that secondary renal
hyperparathyroidism could cause ionized hypercalcemia in
cats with CKD,9,13 hypercalcemia often appears
parathyroid-independent, with secondary suppression of
parathyroid hormone (PTH) secretion.14,15
Calcitonin is released by C-cells of the thyroid in
response to an increased serum ionized calcium concentra-
tion.16,17 It protects against hypercalcemia by inhibition of
bone turnover17–19 and renal reabsorption of calcium,20 but
does not appear to have an important physiologic role in all
species.21 Only 5 of 18 cats with ionized hypercalcemia had
measurable plasma calcitonin concentrations,a and an
increase in plasma calcitonin was observed in just 6 of 13
healthy cats in response to acute hypercalcemia induced by
calcium chloride infusion.22 The absence of a calcitonin
response could cause cats to be susceptible to the develop-
ment of hypercalcemia. The kidneys are the most important
site for calcitonin degradation.23 Calcitonin concentrations
are increased in human CKD patients from stage 3 onwards,
although this possibly is caused by C-cell hyperplasia rather
than reduced metabolism.24,25 Healthy and azotemic normo-
calcemic cats generally appear to have undetectable plasma
calcitonin concentrations.b,22
To date, no longitudinal studies have been published
that explore the relationship between plasma calcitonin
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and ionized calcium and other clinicopathological varia-
bles involved in calcium homeostasis in cats with concur-
rent naturally occurring ionized hypercalcemia and CKD.
Therefore, the aims of our study were to explore these
relationships.
Methods
Case Selection
Cats diagnosed with azotemic CKD and concurrent ionized hyper-
calcemia between January 2002 and March 2014 were retrospectively
identified from the records of 2 first opinion practices in central London
(Beaumont Sainsbury Animal Hospital in Camden and People’s Dis-
pensary for Sick Animals in Bow). Azotemic CKD had been diagnosed
based on a plasma creatinine concentration 2 mg/dL in conjunction
with a urine specific gravity (USG) <1.035, or a plasma creatinine con-
centration 2 mg/dL on 2 consecutive visits 2–4 weeks apart. A blood
ionized calcium concentration >1.37 mmol/L was classified as hyper-
calcemia based on a previously derived reference interval in healthy
age-matched cats.26 Cats were included in this study if data on blood
ionized calcium concentration were available for at least 2 visits within
a 12-month period with blood ionized calcium concentration exceeding
1.37 mmol/L on at least one of these visits, and if stored heparinized
plasma samples obtained on those visits were available for measure-
ment of plasma calcitonin concentrations. Cats with medical treatment
for hyperthyroidism, clinical signs of hyperthyroidism, plasma total thy-
roxine concentration >40 nmol/L, previous bilateral thyroidectomy,
diabetes mellitus, or receiving glucocorticosteroids or diuretics were
excluded from analysis. Cats treated for systemic hypertension with
amlodipine besylate were eligible to be included in the study. For all
cats with azotemic CKD it was advised they be fed a clinical renal diet
and, if necessary, phosphate binders had been added to the treatment.
Cats receiving these forms of PO phosphate restriction were eligible for
inclusion in this study.
Cats were reexamined approximately every 8 weeks for management
of CKD. Clinic visits consisted of full history and physical examination,
systolic blood pressure (SBP) measurement,27 and blood and urine sam-
ple collection. Collection and storage of blood and urine samples had
been performed with owner consent and approval of the Ethics and
Welfare Committee of the Royal Veterinary College. Blood samples
were obtained via jugular venipuncture and urine samples via cysto-
centesis. After ionized calcium concentration and blood gases had been
measured directly following venipuncture in non-heparinized whole
blood using a point-of-care analyzer,c blood was collected in hepari-
nized and EDTA plasma tubes.
All samples were stored on ice for a maximum of 6 h until centrifu-
gation and separation. Heparinized plasma was sent to an external labo-
ratory for biochemical analysis.d Urine samples underwent in-house
urinalysis including measurement of USG by refractometry, dipstick
analysis, and urine sediment microscopic examination. Residual blood
and urine samples were stored at 2808C for future measurement of
plasma PTH, calcidiol, calcitriol, and calcitonin concentrations, and uri-
nary creatinine, calcium, and phosphate concentrations.
Parathyroid hormone was measured in EDTA plasma using a previ-
ously validated intact PTH immunoradiometric assaye with a lower
limit of detection of 5.2 pg/mL.28 Samples with a concentration below
this value were assigned an arbitrary PTH concentration of 2.6 pg/mL.
Results of calcidiol and calcitriol concentrations were available for
some cats, and had been measured at an external laboratory.f Urine bio-
chemistry was performed by a commercial laboratoryd in order to calcu-
late the fractional excretion (FE) values of calcium and phosphate using
the spot sample method.g
Measurement of Plasma Calcitonin Concentration
Calcitonin was measured in heparinized plasma by an immunoradio-
metric assay developed for human serumh for every visit where stored
plasma and data on ionized calcium concentrations were available. This
assay had previously been validated for use on feline heparinized
plasma samples.22 A standard of 3 pg/mL, derived by dilution of the 30
pg/mL standard with deionized water, was added to the standard curve.
The lower limit of detection of the immunoradiometric assay, deter-
mined as the mean1 10 standard deviations (SD) of 8 consecutive
measurements of the zero standard of the assay, was 1.2 pg/mL. Cats
with plasma calcitonin concentrations below this value were assigned
an arbitrary concentration of 0.6 pg/mL for statistical analysis. Hepari-
nized plasma samples for measurement of calcitonin had been stored at
2808C for a median of 1,055 [766, 2,239] days. No significant correla-
tion was found between storage time and plasma calcitonin concentra-
tion for the cats included in this study (sb520.10; P5 0.45; n5 33).
Statistical Analyses
Statistical analyses were performed using statistical software packag-
es.i For all reported analyses 2-sided tests of significance were carried
out with an alpha level of 0.05 defining statistical significance. Continu-
ous clinical data are presented as mean (SD) or as median [25th, 75th
percentiles] as appropriate. The distribution of numerical variables was
assessed for normality by the Shapiro–Wilk test and by visual inspec-
tion of quantile-quantile plots. The assumption of equal variances was
tested with Levene’s test.
The study population was divided into 2 groups: cats that had a
measurable increase in plasma calcitonin concentration in response to
ionized hypercalcemia (responders) and cats that did not have an
increase in plasma calcitonin concentration in response to ionized
hypercalcemia (nonresponders).
Comparison of Responders versus Nonresponders
Clinical data obtained at each cat’s visit with the highest whole
blood ionized calcium concentration were used for this part of the
study. Comparisons between groups were made either with independent
2-sample t-tests for continuous variables with a normal distribution, or
with Mann–Whitney U-tests for skewed variables or if group size was
<5. Proportions were compared with Fisher’s exact test. The hypercal-
cemic responders were compared to nonresponders primarily to assess
group differences in blood ionized calcium concentration, plasma total
alkaline phosphatase (ALP) activity, and FE of calcium, and second to
identify any difference in other clinicopathological variables that could
be related to a calcitonin response. Plasma total ALP was used as a
marker of bone formation. Total ALP activity in serum of mature,
healthy cats is mainly comprised of liver-specific ALP, followed by
bone-specific ALP,29 a marker of osteoblastic bone formation.30 Bone-
specific ALP is more reliable, but total ALP can be used to assess bone
turnover,31–33 although it has not been explicitly validated for this pur-
pose in cats. Cats with concurrent abnormal changes in plasma alanine
transaminase activity were excluded from this analysis to minimize the
impact of liver-specific ALP.
Given that multiple cats had their plasma calcitonin concentration
below the lower limit of detection, the relationship between plasma cal-
citonin concentration and other clinicopathological variables was
assessed by calculating the Kendall’s rank correlation coefficient tau-b
(sb),
34 which is a preferred nonparametric measure of correlation for
analysis of data with ties or small sample size.35,36
Longitudinal Analysis of Responders
To characterize the relationship between plasma calcitonin and blood
ionized calcium concentration within individual cats over time, data
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from available follow-up samples of responders were used to calculate
the within-subject correlation37 of plasma calcitonin with ionized cal-
cium using a bivariate linear mixed effects model.38 Specifically,
unstructured (co)variance types were used between random effects of
plasma calcitonin and random effects of ionized calcium as well as
between the residuals of these 2 variables. By the same method, the
within-subject correlations in responders were calculated between
plasma calcitonin concentration and plasma total ALP activity, FE cal-
cium, and other clinicopathological variables involved in calcium
homeostasis (plasma total calcium, phosphate, PTH, calcitriol, and cal-
cidiol concentrations, venous pH and bicarbonate concentration
[HCO23 ], and FE phosphate). Plasma calcitonin, PTH and calcitriol
were log-transformed before analysis (logarithmus naturalis). No miss-
ing data imputation was performed. The assumptions of normality and
of linear relationship between variables were checked by visual inspec-
tion of histograms of the residuals and scatter plots of the residuals
against the fitted values. Results are presented as within-subject correla-
tion coefficient (rwithin; 95% confidence intervals [95% CI]). Correla-
tions were considered statistically significant if the 95% CI did not
include zero.
Results
Between January 2002 and March 2014, 68 individual
cats with azotemic CKD were diagnosed with ionized
hypercalcemia during the course of their CKD. Thirty-five
cats were excluded from this study because of concurrent
hyperthyroidism (n5 7), previous bilateral thyroidectomy
(n5 1), insufficient follow-up (n5 20), or not having a
stored residual plasma sample available for measurement of
calcitonin (n5 7), allowing 33 cats for analysis. These cats
were of the following breeds: domestic shorthair (n5 23),
domestic longhair (n5 3), Persian (n5 2), Burmese (n5 2),
and 1 each of Abyssinian, British blue, and Cornish rex.
Seventeen cats were of male sex, of which 1 was entire, and
16 cats were female neutered. According to International
Renal Interest Society guidelines (http://iris-kidney.com/
guidelines/staging.html), 26 cats had Stage 2 CKD, 6 had
Stage 3 CKD, and 1 had Stage 4 CKD. Three cats were
treated PO with aluminum hydroxide, 1 cat with chitosan,
and 5 cats with amlodipine besylate.
Based on each cat’s visit with the highest ionized calcium
concentration, median whole blood ionized calcium concen-
tration of the 33 hypercalcemic cats was 1.50 [1.45, 1.65]
mmol/L (range, 1.39–1.93). Followed over time, no
response of calcitonin to ionized hypercalcaemia could be
detected in 22 cats (nonresponders; Fig 1), as plasma calci-
tonin concentrations were persistently below the lower limit
of detection on all available visits (58 clinic visits: 8 cats
with 2 visits and 14 cats with 3 visits available). Measurable
plasma concentrations of calcitonin were observed in 11 of
33 hypercalcemic cats, and the highest plasma calcitonin
concentrations (median, 4.7 [2.1, 28.4] pg/mL; range,
1.7–87.2) coincided with the highest ionized calcium con-
centrations in these responders (31 available visits: 4 cats
with 2, 5 cats with 3, and 2 cats with 4 visits available). In 3
responders, measurable plasma calcitonin concentrations
were observed not only while being hypercalcemic but also
while their ionized calcium concentration was within refer-
ence interval.
Comparison of Responders versus Nonresponders
No evidence was found for a relationship between the fre-
quency of showing a calcitonin response and IRIS stage
(P5 0.76), with 10 of 26 cats with IRIS Stage 2 CKD and
1 of 6 cats with IRIS Stage 3 CKD showing a response of cal-
citonin to ionized hypercalcemia. Six of 11 responders were
male, and no relationship was found between sex and the fre-
quency of showing a calcitonin response by Fisher’s exact
test (P5 1). The Mann–Whitney U-test indicated that the
median maximum ionized calcium concentration of
responders (median, 1.59 [1.46, 1.66] mmol/L; range,
1.42–1.93) was not significantly different from that of the 22
nonresponders (median, 1.48 [1.43, 1.65] mmol/L; range,
1.39–1.84; P5 0.22; Table 1). Mean plasma total ALP activ-
ity was not significantly different between nonresponders
(mean, 26 IU/L; SD, 9.6; n5 18) and responders (mean, 22
IU/L; SD, 2.8; n5 8; P5 0.13). Median FE of calcium val-
ues did not differ significantly between groups (P5 0.11;
Fig 2), although could be calculated only for a small number
of cats because availability of urine samples was limited to 7
nonresponders and 4 responders. Responders did not differ
significantly from nonresponders in any clinicopathological
variable other than a higher HCO23 (responders: mean, 22
mEq/L; SD, 2.1; n5 11, and nonresponders: mean, 19 mEq/
L; SD, 3.5; n5 20; P5 0.034). Storage time of plasma sam-
ples was not significantly different between responders
(median, 925 [724, 1,561] days) and nonresponders (median,
1,080 [775, 2,353] days; P5 0.35).
No correlation between plasma calcitonin and blood ion-
ized calcium concentration was evident in hypercalcemic
cats (sb5 0.14; P5 0.31; n5 33, Fig 3), nor in the group of
responders when analyzed separately (sb520.22; P5 0.35;
n5 11). Plasma calcitonin did not correlate either with
plasma total ALP (sb520.10; P5 0.53; n5 26) or FE of
calcium (sb 5 0.42; P5 0.10; n5 11), nor with any other
clinicopathological variable (results not shown).
Longitudinal Analysis of Responders
Within individual responders, changes in plasma calcitonin
concentration were generally paralleled by changes in blood
ionized calcium concentration over time (Fig 4). The within-
subject correlation coefficient of plasma calcitonin and ion-
ized calcium was 0.83 (95% CI, 0.63–0.92; n5 11), which is
considered statistically significant as the 95% CI did not
include zero. Plasma calcitonin moreover showed a statisti-
cally significant positive within-subject correlation with
plasma total calcium (0.81; 95% CI, 0.59–0.92; n5 11), and
a significant inverse within-subject correlation with plasma
total ALP (20.55; 95% CI, 20.79 to 20.16; n5 8). Limited
information was available for calculation of the within-
subject correlation coefficient of calcitonin with FE of cal-
cium, which was apparent by the wide CI that included zero
(0.46; 95% CI,20.08 to 0.79; n5 4). Results from the bivari-
ate linear mixed effects models can be found in Table 2.
Discussion
In our retrospective study a measurable increase in
plasma calcitonin concentration in response to ionized
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hypercalcemia occurred in a third of cats with azotemic
CKD. In this group of responders, a positive relationship
between plasma calcitonin and blood ionized calcium con-
centration and an inverse relationship between plasma calci-
tonin concentration and total ALP activity appeared to exist
within individual cats over time. No difference in severity
of ionized hypercalcemia was observed between cats that
showed an increase in plasma calcitonin and their non-
responding counterparts.
Plasma calcitonin concentrations were generally low in cats
with azotemic CKD that developed ionized hypercalcemia.
Previously we reported low plasma calcitonin concentrations
in normocalcemic cats with renal azotemiab (<1.2 pg/mL in
all 15 cats) and in hyperthyroid cats (1.2 pg/mL in 4 of 37
cats with a maximum concentration of 2.4 pg/mL).j Others
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Fig 1. Changes in blood ionized calcium concentrations in the sub-
group of nonresponders over time. Even though blood ionized cal-
cium concentration exceeded 1.37 mmol/L on at least one visit in all
22 cats, plasma calcitonin concentration remained below the lower
limit of detection of the immunoradiometric assay (1.2 pg/mL)
throughout follow-up.
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Fig 2. Scatter dot plot illustrating the fractional excretion (FE) val-
ues of calcium in the subgroups of responders (n5 4) and nonres-
ponders (n5 7). Fractional excretion values were obtained by the spot
sample approach. The Mann–Whitney U-test indicated that the
median fractional excretion values of calcium did not differ signifi-
cantly between the 2 groups (P5 0.11).
Table 1. Selected clinicopathological variables of hypercalcemic cats grouped according to whether a calcitonin response
to ionized hypercalcemia was observed (responders, n5 11) or not (nonresponders, n5 22).
Nonresponders (n5 22) Responders (n5 11)
Variable (reference interval) Median [25th, 75th Percentile] n Median [25th, 75th Percentile] n P
Calcitonin (pg/mL) 0.6 [0.6, 0.6] 22 4.7 [2.1, 28.4] 11
Ionized calcium (1.19–1.37 mmol/L) 1.48 [1.43, 1.65] 22 1.59 [1.46, 1.66] 11 0.22
Total ALP (60 IU/L) 26 [16, 32] 18 22 [19, 23] 8 0.13
FE calcium (%) 0.73 [0.19, 1.15] 7 1.16 [1.07, 1.60] 4 0.11
Age (years) 13.4 [11.7, 16.3] 22 12.5 [10.1, 16.6] 11 0.85
Weight (kg) 4.08 [3.29, 4.71] 22 4.51 [3.14, 4.85] 11 0.64
Albumin (2.5–4.5 g/dL) 3.23 [2.97, 3.36] 21 3.10 [2.94, 3.41] 11 0.57
Creatinine (0.23–2.00 mg/dL) 2.2 [2.0, 2.9] 21 2.7 [2.3, 2.7] 11 0.39
USG (1.035) 1.021 [1.018, 1.026] 10 1.019 [1.017, 1.022] 6 0.29
Phosphate (2.79–6.81 mg/dL) 4.27 [3.72, 4.57] 21 3.93 [3.47, 4.03] 11 0.061
FE phosphate (%) 29 [19, 52] 7 29 [23, 38] 4 0.79
tCa (8.2–11.8 mg/dL) 11.7 [11.1, 12.6] 21 12.5 [11.4, 13.0] 11 0.40
Total protein (6.0–8.0 g/dL) 7.85 [7.53, 8.37] 21 7.85 [7.48, 8.32] 11 0.78
PTH (2.6–17.6 pg/mL) 2.6 [2.6, 2.6] 7 2.6 [2.6, 2.6] 4 1
Calcidiol (65–170 nmol/L) 85 [78, 149] 5 139 [79, 159] 4 0.56
Calcitriol (90–342 pmol/L) 108 [65, 161] 5 132 [59, 170] 4 0.84
HCO23 (17–24 mEq/L) 19 [17, 22] 20 22 [21, 23] 11 0.034
Venous pH (7.21–7.44) 7.34 [7.27, 7.38] 20 7.33 [7.32, 7.38] 11 0.46
PCV (30–45%) 35 [30, 38] 22 33 [31, 36] 11 0.51
Sodium (145–157 mEq/L) 152 [151, 155] 19 155 [153, 157] 10 0.33
Potassium (3.5–5.5 mEq/L) 4.1 [3.7, 4.4] 19 4.3 [4.0, 4.4] 10 0.59
Chloride (100–124 mEq/L) 120 [118, 123] 19 119 [118, 121] 10 0.58
SBP (<160 mmHg) 138 [118, 145] 22 142 [120, 146] 0.88
Values are presented as median [25th, 75th percentile], and were derived at each cat’s available visit with the highest ionized calcium concen-
tration. Group comparisons were made by independent sample t-test or Mann–Whitney U-test. All cats had azotemic CKD. ALP, alkaline phos-
phatase; FE, fractional excretion; USG, urine specific gravity; PTH, parathyroid hormone; HCO23 , bicarbonate; PCV, packed cell volume; SBP,
systolic blood pressure.
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have observed low plasma calcitonin values in normocalcemic
healthy cats (maximum, 3.2 pg/mL).22 Low circulating calci-
tonin concentrations (<10 pg/mL) are considered normal in
healthy humans, but up to 30% of human CKD patients have
increased plasma calcitonin concentrations in the absence of
hypercalcemia.21,24,39–42 This secondary hypercalcitoninemia
could either be explained by decreased degradation,21 as calci-
tonin is predominantly degraded by the kidneys,23 or more
likely, by increased secretion, as C-cell hyperplasia is com-
monly associated with hypercalcitoninemia in humans with
CKD.25,41,43 If secondary hypercalcitoninemia was to occur in
feline CKD, this may not have been identified in our study
because the majority of cats had IRIS Stage 2 CKD, whereas
secondary hyperplasia might arise only in more advanced
disease.43,44
The foremost function of calcitonin is thought to be low-
ering of blood calcium concentration, and so to protect
against hypercalcemia.21 However, a calcitonin response
appears to be absent in the majority of cats with azotemic
CKD as only a 3rd showed an increase in plasma calcitonin
in response to naturally occurring ionized hypercalcemia.
Previously, 6 of 13 cats responded to acute hypercalcemia
in an experimental study (maximum plasma calcitonin con-
centration, 43.5 pg/mL)22 and measurable calcitonin values
were observed in 5 of 18 cats included in a cross-sectional
study of cats with naturally occurring ionized hypercalcemia
(maximum, 22.9 pg/mL).a Moreover, loss of calcitonin
secretory ability following bilateral thyroidectomy does not
result in hypercalcemia in cats.45 Absence of a calcitonin
response has also been observed in humans with experimen-
tally induced hypercalcemia, predominantly in women.46,47
Except for higher numbers of calcitonin-positive C-cells in
thyroid tissue of cats that showed a calcitonin response, the
above-mentioned experimental study found no difference in
sex or any other characteristic between responders and
nonresponders.22 In agreement with this, no clear differen-
ces between the 2 groups were identified in our population
of hypercalcemic cats with azotemic CKD. It could be
speculated that individual variation in the number of
calcitonin-expressing C-cells explains why some cats
appear able to increase plasma calcitonin in response to
hypercalcemia, while others appear unable to,22 and it is
interesting in this respect that nonresponders in our study
did not have measurable plasma calcitonin concentrations at
any visit. However, no thyroid tissue was available for his-
topathologic examination to explore calcitonin expression
in cats included in our study. Increases in plasma calcitonin
in response to hypercalcemia could have been missed in
nonresponders. The sensitivity of the assay may have been
too low to detect an actual change in calcitonin in many
cats. Perhaps increases in plasma calcitonin were detected
only in those cats with the most marked increase in calcito-
nin which exceeded the lower limit of detection, and there
might be a subset of cats with smaller increases in calcitonin
that could not be identified. In addition, chronic hypercalce-
mia might temporarily use up the calcitonin content of the
thyroid gland and thereby prevent further secretion.48
No correlation between plasma calcitonin and ionized
calcium was observed in our cross-section of hypercalcemic
cats with CKD, nor in the group of responders when ana-
lyzed separately. This is in agreement with the results of the
previous cross-sectional study among cats with ionized
hypercalcemia.a It has been questioned if plasma calcitonin
is actually related to calcium metabolism.a,49 Nonetheless,
the mentioned experimental study showed that some cats
respond directly to calcium infusion with an increase in
plasma calcitonin.22 Their observation that this response is
heterogeneous between cats may explain the lack of correla-
tion found between calcitonin and ionized calcium or any
other clinicopathological variable. This study found suffi-
cient evidence to support a positive within-subject correla-
tion between plasma calcitonin and ionized calcium. Thus,
within an individual cat these 2 variables were likely to
change in parallel over time. Calcitonin secretion therefore
appeared to be stimulated by ionized calcium, albeit only in
a minority of cats. Severity of hypercalcemia did not differ
significantly between responders and nonresponders in this
study. Even though the query whether increases in blood
ionized calcium concentration were limited by calcitonin
release in responders could not be assessed because of the
observational design of our study, this result is in agreement
with the previous finding that absence of calcitonin secre-
tion did not result in more severe hypercalcemia in cats
infused with calcium chloride.22 Therefore, the role of calci-
tonin in the prevention and restriction of ionized hypercal-
cemia in cats remains to be elucidated.
Calcitonin is thought to exert its hypocalcemic effect
mainly through its inhibitory action on bone turnover.50 It
presumably inhibits osteoclast-mediated stimulation of
osteoblast activity, and thereby indirectly reduces bone for-
mation.19,51 In addition, high or potent doses of calcitonin
were shown to directly inhibit osteoclastic bone resorp-
tion.18 Data on bone turnover markers were not available
for cats included in this study, except for plasma total ALP
activity. A significant inverse relationship between plasma
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Fig 3. Scatter plot illustrating the relationship between plasma calci-
tonin and blood ionized calcium concentrations in hypercalcemic cats
with azotemic CKD. Kendall’s rank correlation indicated that no rela-
tionship was apparent between the 2 variables in the group of hyper-
calcemic cats as a whole (n5 33), nor when the subgroup of
responders was analyzed separately (sb520.22; P5 0.349; n5 11).
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Fig 4. Changes in plasma calcitonin and blood ionized calcium concentrations in the 11 individual responders over time. Plasma calcitonin con-
centration (pink squares, left y-axis) and blood ionized calcium concentration (black dots, right y-axis) tended to change in parallel over time
within each individual cat, resulting in a significant within-subject correlation (0.83; 95% CI, 0.63–0.92; n5 11) as calculated with a bivariate lin-
ear mixed effects model.
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calcitonin and total ALP was apparent within individual cats
over time, which might suggest a possible inhibitory effect
of calcitonin on bone formation in hypercalcemic cats. It
must be pointed out, however, that the observed changes in
plasma total ALP activity over time were small, and so the
effect of calcitonin on bone, if any exists, appears minor.
Moreover, the observed association of calcitonin with
plasma total ALP over time may have been caused by a vari-
able other than calcitonin. Calcium itself negatively regu-
lates the activity and release of ALP from osteoblasts.52–54
Thus, it might be that instead of plasma calcitonin, changes
in ionized calcium, or another variable such as PTH, insti-
gated the observed change in plasma total ALP, but it should
be remembered that the observational design of this study
does not allow for any conclusions on causation.
The presented results were derived from a low number of
observations, and data for variables of interest were not
available for all cats at every visit because of the retrospec-
tive design of our study. This should be carefully considered
when extrapolating the results of this study to the general
feline CKD population. Limited availability of information
resulted in within-subject correlation coefficients with wide
CIs often including zero and may explain a lack of statisti-
cally significant findings. The underlying causes of hyper-
calcemia for cats included in our study remain unknown,
because often no further investigation had been performed.
No signs of neoplasia were recorded although cats included
in this study did not undergo diagnostic imaging.
The physiological value of calcitonin in mammals has
been debated and appears distinct among different
species.21,49,50,55,56 It appears to play an important role in
calcium homeostasis in horses, for example,57 but less so in
humans in which neither hypercalcitoninemia nor low circu-
lating calcitonin concentrations have been associated with
calcium derangements.21 Our study in azotemic cats with
ionized hypercalcemia found calcitonin to change in parallel
with calcium in a subset of cats. Although its restrictive
effect on incidence and severity of hypercalcemia could not
be properly assessed, calcitonin release did not appear to
prevent hypercalcemia in cats and no significant difference
was observed in maximum blood ionized calcium concen-
tration between responders and nonresponders. Therefore,
the relative importance of calcitonin in calcium homeostasis
in cats with azotemic CKD appears minor.
Footnotes
a Maniaki E, Pineda C, Dunbar Z, Finch N. Calcitonin response to
naturally occurring hypercalcaemia in cats. J Small Anim Pract
2016; 57:32–33 (abstract)
b Van den Broek DHN, Geddes RF, Williams TL, et al. Calcitonin
response to naturally occurring ionized hypercalcaemia in cats with
chronic kidney disease. J Small Anim Pract 2016;57:32 (abstract)
c iSTAT 1 point-of-care analyzer, Abbott Point of Care Inc,
Princeton, NJ
d Idexx Laboratories, Wetherby, United Kingdom
e Total intact PTH immunoradiometric assay—coated bead version,
3KG600, Scantibodies, Santee, CA
f Michigan State University Diagnostic Center for Population and
Animal Health, Lansing, MI
g FE of analyte (%)5 100 3 ([urine analyte][serum creatinine]/
[serum analyte][urine creatinine])
h Calcitonin immunoradiometric assay—coated tube technology,
3KG556, Scantibodies, Santee, CA
i IBM SPSS Statistics for Windows, Version 22, IBM Corp., Armonk,
NY and GraphPad Prism 7, GraphPad Software, La Jolla, CA
j Williams TL, Van den Broek DHN, Elliott J, Syme HM. Does
hypercalcitoninism contribute to hypocalcemia in hyperthyroid cats?
J Vet Intern Med 2017;31:221–222 (abstract)
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Table 2. Within-subject correlation of log-transformed
plasma calcitonin concentration with other clinicopathologic
variables in the group of responders calculated with a
bivariate linear mixed effects model.
rwithin 95% CI n
Ionized calcium 0.83 0.63 to 0.92 11
Total ALP 20.55 20.79 to 20.16 8
FE Calcium 0.46 20.08 to 0.79 4
Total calcium 0.81 0.59 to 0.92 11
ln(Calcitriol) 20.33 20.84 to 0.50 4
HCO23 0.26 20.17 to 0.61 11
pH 20.20 20.57 to 0.24 11
ln(PTH) 20.19 20.69 to 0.44 4
Calcidiol 20.15 20.74 to 0.56 4
Phosphate 20.12 20.50 to 0.30 11
FE Phosphate 20.01 20.43 to 0.41 4
Statistically significant positive correlations of plasma calcitonin
with both blood ionized and plasma total calcium concentrations were
evident within individual responders over time. A statistically signifi-
cant negative correlation was apparent between plasma calcitonin and
plasma total ALP activty within individual responders over time.
rwithin, within-subject correlation coefficient; 95% CI, 95% confi-
dence interval; ALP, alkaline phosphatase; ln, natural logarithm; FE,
fractional excretion; HCO23 , bicarbonate.
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